Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers looking at multiple sclerosis investigate using drugs normally prescribed for other diseases.

Affecting 1 in 1,000 people, multiple sclerosis (MS) is an autoimmune disease in which the body’s immune system attacks its own brain and spinal cord.

Professor Lars Fugger’s research at the Nuffield Department of Clinical Neurosciences has found that a drug used to treat hypertension also has some efficacy against neurodegeneration, which is part of MS.

I've seen over the years that there is light at the end of the tunnel, and that if you just push, you will make a difference. - Professor Lars Fugger

MS seems to share some factors with two different groups of diseases: those involving the immune system, such as rheumatoid arthritis, psoriasis and type 1 diabetes; and those involving neurodegenerative conditions of the brain, as in Parkinson’s disease and Alzheimer’s. Data sets relating to all these are being analysed for any patterns or commonalities which could help in identifying new therapeutic strategies against MS.

Read more on the Oxford Thinking website...

Similar stories

Study reveals association between diagnosis of a neuropsychiatric condition and severe outcome from COVID-19 infection, and other severe acute respiratory infections

New research from the University of Oxford has shown an increased risk of severe illness and death from both COVID-19 and other severe respiratory infections, such as influenza and pneumonia, among people with a pre-existing mental health condition.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.

Visit from the Sir Jules Thorn Charitable Trust

Earlier this month, we were delighted to welcome the Director of the Sir Jules Thorn Charitable Trust, Richard Benson, and its Chair of Trustees, Liz Charal.

Oxford receives £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. Our department will play a major role.